Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?

Summary Rationale Little is known about the use of biomarkers in guiding treatment decisions in routine asthma management. The objective of this study was to determine whether adding a LABA to an ICS would control bronchial hyperresponsiveness (BHR) at an overall lower dose of ICS when titration of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory medicine 2008-05, Vol.102 (5), p.665-673
Hauptverfasser:	Koenig, Steven M, Murray, John J, Wolfe, James, Andersen, Leslie, Yancey, Steve, Prillaman, Barbara, Stauffer, John, Dorinsky, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adolescent Adult Aged Aged, 80 and over Albuterol - administration & dosage Albuterol - analogs & derivatives Albuterol - therapeutic use Androstadienes - administration & dosage Androstadienes - therapeutic use Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - therapeutic use Area Under Curve Asthma Asthma - drug therapy Asthma - physiopathology Biological and medical sciences Bronchial Hyperreactivity - diagnosis Bronchial Hyperreactivity - drug therapy Bronchial hyperresponsiveness Bronchoconstrictor Agents Bronchodilator Agents - administration & dosage Bronchodilator Agents - therapeutic use Child Chronic obstructive pulmonary disease, asthma Disease Double-Blind Method Drug Administration Schedule Drug therapy Drug Therapy, Combination Female Fluticasone Fluticasone propionate Humans Latin America Latvia Long-acting beta-agonists Male Medical sciences Metered Dose Inhalers Methacholine Methacholine Chloride Middle Aged Nitric oxide Patient Selection Pneumology Practice Guidelines as Topic Pulmonary/Respiratory Salmeterol Salmeterol Xinafoate Studies Treatment Outcome United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!